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ABSTRACT
Global mechanisms defining the gene expression
programs specific for hematopoiesis are still not
fully understood. Here, we show that promoter
DNA demethylation is associated with the activation
of hematopoietic-specific genes. Using genome-
wide promoter methylation arrays, we identified
694 hematopoietic-specific genes repressed by
promoter DNA methylation in human embryonic
stem cells and whose loss of methylation in hem-
atopoietic can be associated with gene
expression. The association between promoter
methylation and gene expression was studied for
many hematopoietic-specific genes including
CD45, CD34, CD28, CD19, the T cell receptor
(TCR), the MHC class II gene HLA-DR, perforin 1
and the phosphoinositide 3-kinase (PI3K) and
results indicated that DNA demethylation was not
always sufficient for gene activation. Promoter
demethylation occurred either early during embry-
onic development or later on during hematopoietic
differentiation. Analysis of the genome-wide
promoter methylation status of induced pluripotent
stem cells (iPSCs) generated from somatic CD34
+
HSPCs and differentiated derivatives from CD34
+
HSPCs confirmed the role of DNA methylation in
regulating the expression of genes of the
hemato-immune system, and indicated that
promoter methylation of these genes may be
associated to stemness. Together, these data
suggest that promoter DNA demethylation might
play a role in the tissue/cell-specific genome-wide
gene regulation within the hematopoietic
compartment.
INTRODUCTION
The orchestrated regulation of genome-wide gene expres-
sion directs the complex logistics of cell fate determination
during the development/ontogeny of higher organisms.
Whereas some genes are constitutively expressed through-
out the different developmental stages, others are specif-
ically expressed in a temporal (i.e. developmental stage)
and spatial (i.e. lineage speciﬁc) fashion. Regulation of
gene expression in blood cell development is of particular
interest, given the diversity of functionally different hem-
atopoietic cell types and the large range of hematological
malignancies affecting a variety of hematopoietic cell
subsets (B-cells, T-cells, NK-cells, myeloid cells, red
blood cells, platelets, etc.) at distinct developmental
stages [i.e. stem cell (HSC), B progenitor (pro-B), B pre-
cursor (pre-B), mature B cells, plasma cells, etc.].
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about gene expression patterns in blood cells, there is an
important gap in our understanding about its regulation.
Epigenetic marks participate prominently in gene regu-
lation (1). Genomic DNA methylation, one of the
best-studied epigenetic modiﬁcations, is an important
means of regulating gene expression with alterations in
this process being associated with cancer and other
diseases (1,2). As a means of gene inactivation, DNA
methylation has been implicated in the stable silencing
of undifferentiated embryonic stem cell (ESC)-associated
genes such as OCT4 and NANOG (3,4). Although many
genes are hypermethylated in ESCs, demethylation
processes during cell differentiation have yet to be
studied in depth. Previous genome-wide methylation
studies in ESCs described a scenario in which most of
the CpG-rich promoters were unmethylated, while
CpG-poor promoters, generally associated with highly
tissue-speciﬁc genes, tend to be hypermethylated (5,6).
As certain genes whose expression is restricted to the hem-
atopoietic system, such as the genes for myeloperoxidase
(7), globin (8,9), c-fms (10), lysozyme (11), the granulocyte
colony-stimulating factor (G-CSF) receptor (12), perforin
(13), platelet glycoprotein VI (GPVI/GP6) (14) and
FOXP3 (15) are nonetheless regulated by methylation in
a lineage- and developmental stage-dependent manner, we
hypothesized that promoter demethylation might be an
important mechanism of gene regulation within the hem-
atopoietic system/hierarchy.
We used Inﬁnium DNA methylation arrays to study the
genome-wide role of promoter DNA demethylation in the
hematopoietic system. We have compared the methylation
status of human ESCs, cord blood (CB), CD34
+hemato-
poietic stem and progenitor cells (HSPCs) and ﬁve highly
represented differentiated blood white cell lineages: neu-
trophils, B lymphocytes, NK cells, CD8
+ T lymphocytes
and CD4
+ T lymphocytes. Using this approach in com-
bination with RNA/protein expression experiments, we
identiﬁed several hundreds of genes that become
demethylated during hematopoietic differentiation.
In vitro differentiation of CB-derived CD34
+HSPCs sup-
ported the role of promoter demethylation during hemato-
poietic differentiation. Importantly, analyses of iPSCs
derived from CD34
+ HSPCs demonstrated that the
promoter methylation-associated repression of hemato-
poietic genes is closely associated with stemness and that
most but not all the promoter DNA demethylation
observed during hematopoietic differentiation is reverted
upon cellular reprogramming.
MATERIALS AND METHODS
Human ESC lines
Cell pellets and/or DNA/RNA were used from the follow-
ing well-characterized hESC lines: SHEF-1, SHEF-4,
SHEF-5, SHEF-7, H7, H14, H14S9, H7S14, HS181 and
I3. Human ESCs were maintained undifferentiated in a
feeder-free culture as previously described (16,17).
Brieﬂy, hESCs were cultured in Matrigel (BD
Biosciences, Bedford, MA, USA)-coated T25 ﬂasks in
either mouse embryonic ﬁbroblast (MEF), human
foreskin ﬁbroblast (HFF) or mesenchymal stromal cell
(MSC)-conditioned medium (MEF-CM, HFF-CM or
MSC-CM) supplemented with 8ng/ml basic ﬁbroblast
growth factor (bFGF; Miltenyi, Madrid, Spain)
Approval from the Spanish National Embryo Ethical
Committee (ISCIII) was obtained to work with these
hESCs lines.
Primary tissue
Fresh CB units from healthy newborns were obtained
from The Ma ´ laga Cord Blood Bank upon approval by
local Ethics and Biozahard Board Committee. CB
samples were pooled to reduce variability between individ-
ual freshly isolated CB units (n=5). Mononuclear cells
(MNC) were isolated using Ficoll-Hypaque (GE
Healthcare, Stockholm, Sweden). After erythrocyte lysis
(Lysis solution, StemCell Technologies, Vancouver,
Canada), CD34
+cells were puriﬁed by magnetic bead sep-
aration using the human CD34 MicroBead kit (Miltenyi,
Munich, Germany) and the AutoMACS Pro separator
(Miltenyi) according to manufacturer’s instructions (18).
Lymphocytes and neutrophils were isolated from periph-
eral blood (PB) from healthy adult volunteers by centri-
fugation, using Histopaque-1077 (Sigma, St Louis, MO,
USA). CD4
+ and CD8
+ T cells were enriched from PB
MNCs using magnetic bead isolation (Miltenyi). NK
and B cells were FACS-sorted (FACSAria, Becton
Dickinson, San Jose, CA, USA) based on their speciﬁc
expression of the surface markers CD56 and CD19, re-
spectively. Purity of all isolated cellular fractions was
>95%. Hematological samples were pooled to reduce
interindividual variability (n=5). DNA from human
normal primary tissues was obtained from Biochain
(Hayward, CA, USA).
Generation of iPSC from CD34
+ CB cells
CD34
+ HSCs puriﬁed from CB (1 10
5cells/ml) were
pre-stimulated 48h in Stem Span medium (Stem Cells
Technologies, Grenoble, France) supplemented with
SCF (100ng/ml), FLT3L (100ng/ml) and IL-3
(10ng/ml) in ﬁbronectin-coated plates (Becton
Dickinson) (19). Induced PSC were generated by infection
of prestimulated CD34
+HSC with high-titer viral vectors
expressing the human reprogramming factors Oct4, Sox2,
Klf4 and c-myc (OKSM), as previously described (20).
Viral particles pseudotyped with the VSV-G protein
were generated on 293T cells using a standard calcium–
phosphate transfection protocol and were concentrated by
ultracentrifugation (21). Cells were infected overnight; the
following day, viral supernatant was removed and
transduced CD34
+ HSC were washed with Stem Span
medium and allowed to grow for 3 days before transfer
onto irradiated (4000Gy) HFFs (16). Cultures were main-
tained in KO-DMEM supplemented with 20% serum re-
placement (Invitrogen, Carlsbad, CA, USA), 1%
non-essential amino acids, 1mM L-glutamine, 0.1mM
b–mercaptoethanol and 50ng/ml bFGF). Emerging iPSC
colonies were identiﬁed and passaged onto fresh feeders
(20). iPSC from CB-derived CD34
+ cells were fully
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displayed ESC morphology, ESC-associated transcription
factors and cell surface markers, silenced ectopic
reprogramming factors and they differentiated into the
three germ layers in vitro (embryoid bodies) and in vivo
(teratomas) (22). These iPSC lines have been deposited
according to Spanish Legislation in The Spanish Stem
Cell Bank (http://www.isciii.es/htdocs/terapia/terapia_
lineas.jsp).
DNA methylation proﬁling using bead arrays
Microarray-based DNA methylation proﬁling was per-
formed on all samples with the HumanMethylation27
DNA Analysis BeadChip (Illumina, San Diego, CA,
USA). This array allows interrogation of 27578 highly
informative CpG sites per sample at single-nucleotide
resolution for more than 14000 genes. This 12-sample
BeadChip features content derived from the NCBI
CCDS database (Genome Build 36) and is supplemented
with more than 1000 cancer-related genes.
HumanMethylation27 BeadChip content also targets the
promoter regions of 110miRNA genes. The Inﬁnium
Methylation Assay accomplishes this high multiplexing
by combining bisulﬁte conversion of genomic DNA and
whole-genome ampliﬁcation (WGA) sample preparation
with direct, array-based capture and enzymatic scoring
of the CpG loci. Bisulﬁte conversion of DNA was per-
formed using the EZ DNA Methylation Kit (Zymo
Research, Orange, CA, USA) according to manufacturer’s
procedures, with the modiﬁcations described in the
Inﬁnium Assay Methylation Protocol Guide. Processed
DNA samples were hybridized to the BeadChip
(Illumina). The assay interrogates the chemically
differentiated loci using two site-speciﬁc probes, one
designed for the methylated locus (M bead type) and
another for the unmethylated locus (U bead type).
Single-base extension of the probes incorporates a
labeled ddNTP, which is subsequently stained with a
ﬂuorescence reagent. The methylation level for the
interrogated locus is determined by calculating the ratio
of the ﬂuorescent signals from the methylated versus
unmethylated sites. The ratio of ﬂuorescent signals was
then computed from the two alleles according to the fol-
lowing formula:
Beta¼
Max M,0 ðÞ
Max U,0 ðÞ +Max M,0 ðÞ +100
This beta value is a quantitative measure of DNA
methylation levels of speciﬁc CpG, and ranges from 0
for completely unmethylated to 1 for completely
methylated.
The microarray data from this study have been
submitted to the NCBI Gene Expression Omnibus
(GEO) (http://www.ncbi.nlm.nih.gov/geo) under acces-
sion number GSE30090.
Before analyzing the methylation data, we excluded
possible sources of technical and gender-speciﬁc biases.
Technical bias were minimized by excluding probes with
detection P-values >0.01 in  5% samples. Gender-speciﬁc
bias was avoided by excluding probes in sex
chromosomes.
Differential methylation and computational gene
expression analysis
The amount of bisulﬁte-modiﬁed target DNA that hybrid-
izes to each spot of the Illumina chip was quantiﬁed and
standardized over a range from 0.0 to 1.0 (effectively 0%
and 100% likelihood of gene promoter hypermethylation,
respectively). In this work, all sequences with at least 70%
likelihood of being hypermethylated (hybridization signal
 0.7) were considered hypermethylated for each speciﬁc
sample, whereas sequences whose equivalent signal was
below 30% (hybridization signal <0.3) were considered
unmethylated. For each differentiated tissue, a CpG site
was considered demethylated when it was
hypermethylated in hESC and demethylated in all the
samples corresponding to that speciﬁc tissue. A CpG site
was considered as tissue speciﬁcally demethylated when
it was demethylated exclusively in that tissue or cell
type. In in vitro CD34
+ differentiation (Diff-CD34) and
de-differentiation (CD34-iPSCs) experiments, we only
considered CpG sites showing a change in methylation
values of at least 20% relative to CD34
+ progenitors.
Gene ontology (GO) and database expression analyses
were performed with the DAVID GO Web-based tool
(23,24), comparing demethylated gene groups against a
background comprising all the genes in the Illumina array.
We compared the methylation data with available gene
expression data. For solid tissues and whole-PB gene ex-
pression data was taken from Amazonia (http://amazonia
.transcriptome.eu), which comprises human transcriptome
list annotations. Gene expression data was downloaded
from GEO (http://www.ncbi.nlm.nih.gov/geo) to
compare methylation and expression data in different
PB cell subsets (CD8
+: GSM565269, GSM565270,
GSM565271, GSM565272; CD4
+: GSM565273,
GSM565274, GSM565275; NK: GSM565293,
GSM565294, GSM565295, GSM565296; B
cells: GSM565308, GSM565309, GSM565310,
GSM565311, GSM565312, GSM565313, GSM565314;
neutrophils: GSM565378, GSM565379, GSM565380,
GSM565381, GSM565382). Box plots were used to
estimate the distribution of gene expression (log scale).
In each tissue or cell type, equality of densities referred
to speciﬁc demethylated gene expression levels compared
to the other tissue or cell types was conﬁrmed using L1
criterion (25). We used very restrictive criteria to select
genes with expression associated with speciﬁc
demethylation in a given tissue or blood cell subset
(Supplementary Tables S1 and S2): for each tissue or
cell type, differences (signiﬁcant at 5%) were calculated
between average expression values of speciﬁc genes and
the maximum average of the other tissues (Student’s
t-test). Resample methods were used to conﬁrm or
discard other complex hypotheses.
To determine the role of demethylation in priming genes
for further expression, we compared our methylation data
with the available expression data of activated hematopoi-
etic cells (B cells, CD4
+cells and NK cells) obtained from
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GSM565316, GSM565317, GSM565318; CD4
+:
GSM565276, GSM565277; NK: GSM565302,
GSM565303, GSM565304, GSM565305, GSM565306,
GSM565307). We followed the same criteria mentioned
above to select genes with expression associated with
speciﬁc demethylation in a given blood cell subset
(Supplementary Table S3).
To enable a comparison of gene expression between
lymphoid/myeloid progenitors and terminally
differentiated cell types, we compared our methylation
data with expression data of a subset of hematologic pro-
genitor and terminally differentiated hematological cells
obtained from BioGPS (Hematopoietic Atlas, Data
set_302) (26). We selected those genes whose expression
associated with speciﬁc demethylation in a blood cell
subset was higher than the likelihood thresholds for the
non-speciﬁc ones. These thresholds were computed as
the upper bound in a 95% conﬁdence interval for the
‘non-speciﬁc’ means (Supplementary Table S4).
The clustering heatmaps and bar plots using methyla-
tion and expression data were prepared with BeadStudio
software (Illumina) and Microsoft Excel tools.
Pyrosequencing
Sodium bisulﬁte modiﬁcation of 0.5mg genomic DNA
isolated from various tissues was carried out with the
EZ DNA Methylation Kit following the manufacturer’s
protocol. Bisulﬁte-treated DNA was eluted in 15ml
volumes with 2ml for each PCR. The set of primers for
PCR ampliﬁcation and sequencing were designed using a
speciﬁc software pack (PyroMark assay design version
2.0.01.15). Primer sequences were designed to hybridize
with CpG-free sites to ensure methylation-independent
ampliﬁcation.
PCR was performed with primers biotinylated to
convert the PCR product to single-stranded DNA tem-
plates. We used the Vacuum Prep Tool (Biotage,
Sweden) to prepare single-stranded PCR products accord-
ing to manufacturer’s instructions. Pyrosequencing reac-
tions and methylation quantiﬁcation were performed in a
PyroMark Q24 System version 2.0.6 (Qiagen). Graphic
representation of methylation values shows bars identify-
ing CpG sites that present percentage methylation values.
RNA puriﬁcation and real-time RT–PCR analysis
RNA was isolated with TRIzol Reagent (Invitrogen) ac-
cording to manufacturer’s instructions. For RT–PCR,
1mg total RNA was reverse transcribed using the High
Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). Quantitative real-time RT–PCR was per-
formed using SYBR green universal master mix and the
ABI PRISM 7900 sequence-detection system (Applied
Biosystems). Data are expressed as mean±SD of three
replicates of each experiment.
Western blot
Cell lysates for protein analysis were prepared by
radio-immunoprecipitation assay buffer extraction and
analyzed by western blot using anti-b-actin (Sigma) and
anti-PI3Kd (Santa Cruz).
Flow cytometry
iPSC from CD34
+ cells were harvested with 0.1%
collagenase IV (Invitrogen) and dissociated into single
cells before staining. CD34
+-derived iPSCs and CD34
+
cells (2 10
5) were incubated 30min with the following
ﬂuorochrome-conjugated monoclonal antibodies:
PerCP/Cy5.5-anti-CD34 (Biolegend), PE-anti-CD4,
FITC-anti-CD34, PE-anti-CD28 and PE-anti-CD31 (BD
Biosciences). A ﬂuorochrome-matched isotype control
was always used. The proportion of living, dead and apop-
totic cells were determined with 7AAD and the Annexin
V-FITC apoptosis detection kit (Immunostep, Salamanca,
Spain), as previously described (27). Data acquisition was
carried out in a FACSCanto II Cytometer and data was
analyzed using FACSDiva software (Becton Dickinson).
Colony forming unit assay
The CB-derived CD34
+-enriched fraction
(2 10
3cells/cm
2) was plated in methycellulose-based
medium supplemented with SCF (50ng/ml), GM-CSF
(10ng/ml), IL-3 (10ng/ml) and erythropoietin (3U/ml;
Methocult GF H4434; StemCell Technologies). After
12–14 days in culture, colonies were counted and
scored (28,29). Colonies were subsequently scraped from
the tissue culture plate and used for genomic DNA
extraction.
RESULTS
Identiﬁcation of tissue-speciﬁc promoter-demethylated
genes using bead arrays
We compared the DNA methylation status of 27578 se-
quences in 10 independently isolated human hESC lines
and 16 healthy tissues corresponding to eight normal
tissue types [colon, bone, fat, muscle, liver, thyroid,
brain and blood (PB white cells)], using Illumina
Inﬁnium Methylation Arrays.
For identiﬁcation of tissue-speciﬁc promoter-
demethylated genes, we chose probes that showed methy-
lation values (average_beta) <30% in each tissue type and
methylation values (average_beta)  70% in at least 80%
of the hESC, following previously published criteria (30).
Using this approach, we identiﬁed groups of CpG probes
that were demethylated in each tissue: 227 (corresponding
to 200 genes) in brain, 201 (179 genes) in thyroid, 213 (189
genes) in liver, 283 (263 genes) in colon, 322 (289 genes) in
fat, 229 (213 genes) in bone, 397 (354 genes) in muscle and
540 (463 genes) in blood (Supplementary Table S5 and
Figure 1A). Of these, 23 CpG sites (corresponding to 21
genes) were demethylated speciﬁcally in brain (and in no
other tissue), 25 (24 genes) in thyroid, 8 (8 genes) in liver,
13 (13 genes) in colon, 8 (8 genes) in fat, 7 (7 genes) in
bone, 47 (47 genes) in muscle and 202 (182 genes) in blood
(Supplementary Table S6). 40 CpG sites 110 (36 genes)
were demethylated in all of these tissues, and a total of
Nucleic AcidsResearch, 2012, Vol.40,No. 1 119413 CpG sites (383 genes) were demethylated in more than
one tissue (Supplementary Table S7).
Supervised clustering of samples using exclusively the
methylation signals of the tissue-speciﬁc demethylated
probes (333; 310 genes) enabled correct classiﬁcation of
each sample within its corresponding group (Figure 1B),
indicating that each sample group has a speciﬁc
demethylated promoter signature. Two approaches were
used to determine whether gene promoter demethylation
enables establishment of tissue-speciﬁc expression
programs; we used GO to analyze the function of
tissue-speciﬁc demethylated promoters, and studied the
relationship between our methylation data and published
expression arrays on the tissue-speciﬁc expression of these
genes (Table 1). Analysis of blood- (and less signiﬁcantly
in muscle- and liver-) speciﬁc demethylated promoters
showed non-random distribution of GO terms in the bio-
logical process and cell component categories (Table 1).
Tissue-speciﬁc demethylated genes were enriched for bio-
logical processes terms related to the tissue type in which
they are demethylated (Table 1). In PB, promoter
demethylation was associated predominantly to genes
coding for membrane-associated proteins, whereas in
muscle this was associated to genes encoding proteins
located in contractile ﬁber. Of the 182 genes demethylated
exclusively in blood, 49 (P=4.47 10
 18) were described
by the highest ranking GO term 0002376–immune system
process (Table 1).
Analysis of these sample groups for tissue expression in
databases (UniProt data bank tissue description) showed
that genes demethylated in blood, muscle, brain and liver
were enriched (P<0.05) for expression in these tissues.
To study this issue in more detail, we compared our
methylation data with known expression data for these
genes in blood cells [GEO, http://www.ncbi.nlm.nih.gov/
geo/, see ‘Experimental Procedures’ section and
Figure 1C]. Expression of these genes was restricted
mainly to those cell types in which they are fully
demethylated (Figure 1B). These analyses also showed
that 23.1% of the genes speciﬁcally demethylated
in brain (and in no other tissue), 6.7% in muscle, 10%
in colon, 33.3% in liver, 5.3% in thyroid and 19.3%
in blood were overexpressed in the tissue type in
which they are demethylated (Supplementary Table S1),
suggesting that promoter demethylation is not always
associated with gene expression. These observations
suggest that promoter DNA demethylation might be
involved in tissue-speciﬁc gene expression; given
the larger number of demethylated genes in white blood
cells and their pronounced enrichment for hemato-
immune system-related functions, this mechanism
appears to be particularly relevant for immune system-
speciﬁc genes.
Identiﬁcation of hematological cell type-speciﬁc
demethylated genes
Epigenetic signaling has been implicated in establishment
of the distinct hematological cell types (8,9,11–15,31–33).
For a more detailed study of the cell type-dependent
role of promoter demethylation in hematopoietic differen-
tiation, we used the Inﬁnium arrays for promoter methy-
lation analyses in CD34
+ HSPCs hematopoietic
progenitor cells and ﬁve of the most abundant blood cell
types: PMN (mainly neutrophils) and lymphocytes
(separated as CD19
+B cells, CD56
+NK cells, CD8
+cyto-
toxic T cells and CD4
+ helper T cells). Comparison of
their methylation to that of 10 hESC lines allowed identi-
ﬁcation of 429 CpG sites (382 genes) demethylated in
CD34
+hematopoietic progenitors, 652 (552 genes) in neu-
trophils, 734 (627 genes) in B cells, 516 (463 genes) in NK
cells, 414 (366 genes) in CD8
+T cells and 496 (443 genes)
in CD4
+T cells (Figure 2A and B) (Supplementary Table
S8). Of these CpG sites, 25 (25 genes) were demethylated
speciﬁcally in CD34
+hematopoietic progenitors, 119 (114
genes) in neutrophils, 169 (158 genes) in B lymphocytes, 68
(67 genes) in NK cells, 43 (42 genes) in CD8
+T cells and
66 (65 genes) in CD4
+ T cells (Figure 2B and
Supplementary Table S9).
Of the CpG sites demethylated in CD34
+ HSPCs cells,
42.4% (182/429) were also hypomethylated in all termin-
ally differentiated cells analyzed (Figure 2A). Of the 429
CpG sites demethylated in CD34
+ HSPCs cells, 25 were
not demethylated in terminally differentiated hematologic-
al cells types analyzed, suggesting that these genes are
CD34
+-speciﬁc (Supplementary Table S9). Most
demethylated CpG sites in neutrophils (74.2%, 484/652)
corresponded to genes previously identiﬁed as
demethylated in blood (Figure 1), which can be explained
by the fact neutrophils are the most abundant blood cell
type.
To determine whether blood cell type-speciﬁc
demethylation is restricted to the immune system, we
compared the methylation status of cell type-speciﬁcally
demethylated genes in the various blood cell types and in
other non-hematological cell types (Supplementary Figure
S1). Most of these genes (84.2%, 388/461 corresponding
to 83.5%, 409/490 probes) were demethylated exclusively
in the hematological system (Supplementary Table S10).
Most of the CpG sites demethylated in at least one
of the hematological cell types analyzed (66.44%, 796/
1198; 68.64%, 694/1011 genes) were also demethylated
exclusively in hematological cells (Supplementary
Table S11). Collectively, these data indicate that there
are at least 796 CpG sites (694 genes) that are
demethylated exclusively during hematopoiesis
(Supplementary Table S11), which concurs with our
previous hypothesis that promoter demethylation might
have a role in activation of immune system genes, and
indicates that at least 694 hematologic-speciﬁc genes are
regulated by promoter demethylation, more than the 182
genes identiﬁed in the whole blood sample
(Supplementary Table S6). Based on the position of
CpG detected in the array, the great majority (77.4%) of
demethylated sites were found in low CpG density regions
(Supplementary Table S11), which suggest that non-CpG
island methylation plays an important role in human
hematopoiesis.
To determine whether gene promoter demethylation
participates in the establishment of cell type-speciﬁc ex-
pression programs in blood, we analyzed these sample
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Figure 1. DNA methylation proﬁling in human embryonic stem cell (hESC) lines and normal primary tissues. (A) Matrix showing the number of
demethylated CpG sites in each tissue type and demethylated CpG sites shared between different tissue types. (B) Illumina array methyla-
tion clustering heatmap of hESC-hypermethylated genes speciﬁcally demethylated in each of the eight normal tissue samples. Methylation levels
vary from fully methylated (red) to fully unmethylated (green). (C) Box plots of microarray-based gene expression data (log scale). In each primary
tissue, tissue-speciﬁc demethylated genes exhibited higher expression levels compared to other tissues. P-values are shown. n=number of genes
analyzed.
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bank tissue description) and found that genes
demethylated in neutrophils and B cells are enriched for
expression in these cell types (P<0.05). We compared our
methylation data and earlier reports on the terminally
differentiated blood cell type-speciﬁc expression of these
genes obtained from the GEO database (GSE22886) (see
‘Experimental Procedures’ section and Figure 2C) (34),
and found that the expression of these genes is restricted
mainly to those cell types in which they are fully
Table 1. GO and expression analysis of tissue-speciﬁc demethylated genes
Gene set GO Tissue-speciﬁc expression
GO Term P-value P-value
Blood Biological process UNIPROT tissue
Immune system process 4.47E-18 Blood 1.74E-08
Immune response 1.53E-12 Spleen 1.54E-07
Defense response 1.41E-10 Lymph 4.14E-07
Signal transduction 6.86E-07 Thymus 2.90E-04
Response to stimulus 1.06E-06
Cell activation 2.84E-06
Leukocyte activation 4.35E-05
Innate immune response 4.38E-05
Cell component
Membrane 3.30E-08
Plasma membrane 3.67E-08
Integral to membrane 1.10E-07
Muscle Biological process UNIPROT tissue
Muscle contraction 1.19E-04 Skeletal muscle 3.22E-03
Muscle system process 1.85E-04
Response to reactive oxygen species 1.41E-03
Catabolic process 5.68E-03
Cell component
Contractile ﬁber 1.55E-06
Sarcomere 2.28E-04
Z disc 3.26E-04
Myoﬁbril 3.37E-04
Contractile ﬁber part 3.89E-04
Brain UNIPROT tissue
None Alzheimer cortex 2.71E-02
Brain 4.94E-02
Fetal brain 6.53E-02
Liver Biological process UNIPROT tissue
Amine metabolic process 3.09E-04 Liver 3.19E-02
Hyaluronan metabolic process 3.25E-03
Monocarboxylic acid metabolic process 5.88E-03
Oxoacid metabolic process 1.84E-02
Carboxylic acid metabolic process 1.84E-02
Organic acid metabolic process 1.87E-02
Cellular ketone metabolic process 1.89E-02
Glycosaminoglycan metabolic process 2.16E-02
Nitrogen compound metabolic process 2.22E-02
Aminoglycan metabolic process 2.62E-02
Polysaccharide metabolic process 4.43E-02
Metabolic process 5.53E-02
Fat Biological process
Inﬂammatory response 6.72E-03 None
Response to wounding 1.79E-02
Response to stress 2.00E-02
Defense response 2.16E-02
Response to external stimulus 4.92E-02
Thyroid Biological process
G-protein coupled receptor protein signaling pathway 1.99E-02 None
Negative regulation of caspase activity 3.13E-02
Negative regulation of peptidase activity 3.65E-02
Renal system process 4.50E-02
Hormone biosynthetic process 4.66E-02
Cell component
Extracellular region 1.61E-02
Bone None None
Colon None None
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Figure 2. DNA methylation changes during hematopoietic differentiation. (A) Matrix showing the number of demethylated CpG sites in each
hematopoietic cell subset and demethylated CpG sites shared between distinct hematopoietic cell types. (B) Illumina array methylation clustering
heatmap of SHEF-1 hESC line hypermethylated genes, demethylated in at least one of the six hematopoietic cell types analyzed: CD34
+ HSPCs,
neutrophils, B cells, NK cells, CD8
+ T cytotoxic cells (CD8
+) and CD4
+ T helper cells (CD4
+). Methylation levels are indicated as in Figure 1B.
(C) Box plots of microarray-based gene expression data (log scale). In each blood cell type, speciﬁc demethylated genes exhibited higher expression
levels compared to other cell types. P-values are shown. n=number of genes analyzed.
Nucleic AcidsResearch, 2012, Vol.40,No. 1 123demethylated (Figure 2B). Moreover, these analyses
showed that 17.3% of the genes speciﬁcally demethylated
in neutrophils (and in no other tissue), 22.3% in B
lymphocytes, 2.4% in CD4
+ T cells, 3.7% in CD8
+ T
cells and 9.1% in NK cells were overexpressed in the
tissue type in which they are demethylated
(Supplementary Table S2), suggesting that, as in other
tissues (Supplementary Table S1), promoter
demethylation is not always associated with gene expres-
sion in blood. To study in more detail the relationship
between demethylation and gene expression, we
compared our methylation data with the expression data
of a subset of hematologic progenitor and terminally
differentiated hematological cells obtained from a differ-
ent database (BioGPS, Hematopoietic Atlas,
Dataset_302). These analyses showed that most (68.4%)
of the demethylated genes were overexpressed in the tissue
type in which they are demethylated (Supplementary
Table S4). To determine whether demethylation was im-
portant in priming genes for gene expression upon cell
activation, we compared the methylation data with the
available expression data [GEO database (GSE22886)]
of activated hematopoietic cells (B cells, CD4
+ cells and
NK cells). These analyses showed that 13.7% of the
demethylated genes became overexpressed upon cell acti-
vation (Supplementary Table S3).
To validate the methylation array data, we selected
various genes [PECAM1 (CD31), HLA-DR, CD28,
CD19, CD45, PRF1, PIK3CG, PIK3CD, CD34, CD3]
that are demethylated speciﬁcally in one or several
blood cell types and analyzed their methylation and ex-
pression status in the same type of samples used in
the arrays. In all cases, bisulﬁte pyrosequencing
data corroborated the array results (Figure 3). We
also analyzed gene expression by qPCR to determine
the relationship between DNA methylation and transcrip-
tion. CD19, shown by methylation arrays to be
demethylated exclusively in B cells, showed a high methy-
lation degree in all cell types analyzed except B cells.
Similarly, CD3 was selectively demethylated and ex-
pressed in T cells and PRF1 in CD8
+ T cells and NK
cells. CD45, CD31, PIK3CG and PIK3CD (shown by
methylation arrays to be demethylated in CD34
+ cells
and in all descendants) were demethylated and ex-
pressed at different degrees in all hematological cells.
CD34, HLA-DR and CD28, although demethylated in
CD34
+ precursors and in hematological cells, were ex-
pressed selectively in CD34
+ cells, B and T cells,
respectively.
To study in greater detail the role of promoter
demethylation in the establishment of speciﬁc cell
lineages during hematopoietic differentiation, we
examined the function of cell type-speciﬁc promoter
demethylated genes by GO analyses, which showed
non-random distribution of GO terms, mainly with
respect to biological process (Table 2). GO terms were
highly enriched for immune-related biological processes,
which further supports an important role for promoter
demethylation during hematopoiesis.
Differentiation and dedifferentiation of CD34
+ HSPCs
recapitulate changes in hematopoietic gene methylation
We used a dual approach to conﬁrm the role of promoter
DNA methylation in the regulation of immune system
genes during ontogenic development: (i) a ‘push-forward’
in development approach in which a colony-forming unit
(CFU) assay was carried out to induce in vitro myeloid
differentiation of CD34
+ HSPCs (Diff-CD34
+) and (ii) a
‘push-back’ in development approach in which
pluripotency was induced in CD34
+ HSPCs
(CD34-iPSCs) by viral-based ectopic expression of the
reprogramming factors Oct4, Klf4, Sox2 and c-Myc
(http://www.isciii.es/htdocs/terapia/terapia_lineas.jsp).
Both Diff-CD34 and CD34-iPSC were analyzed by
Inﬁnium arrays in order to compare the genome-wide
promoter methylation status of CD34
+ HSPCs,
Diff-CD34 and CD34-iPSC. We found that 29.7% of
the genes (206/694; 212/767 probes) previously found to
be methylated in CD34
+cells and demethylated in any of
the terminally differentiated hematological cells analyzed
were demethylated in the Diff-CD34 cells (Supplementary
Table S12 and Figure 4). Strikingly, however, when
compared to hESC, 80.1% of the genes (306/382; 341/
429 probes) demethylated in CD34
+ cells were
hypermethylated in CD34-iPS cells, indicating a central
role for promoter DNA methylation in the ontogenic
development-dependent regulation of hematological
genes (Supplementary Table S13 and Figure 4A).
To analyze the relationship between promoter methyla-
tion and gene expression during in vitro differentiation and
induction of pluripotency of CD34
+ HSPCs cells, we
analyzed PIK3CG, PIK3CD, HLA-DR, CD31 and
CD28 by bisulﬁte pyrosequencing, qPCR and ﬂow
cytometry or western blotting. Pyrosequencing data
corroborated array results and showed that hESC methy-
lation affected the majority of the CpG surrounding the
transcriptional start site of the genes selected (Figure 4B
and Supplementary Figure S2). qPCR, ﬂow cytometry
and western blotting experiments conﬁrmed our data
showing that promoter demethylation did not necessarily
involve gene upregulation. Collectively, these results
support our hypothesis that immune system genes must
be strictly regulated during ontogenic development (in
hESC, HSC and terminally differentiated cells) and that
DNA methylation might play an important role in this
process.
DISCUSSION
Hematopoiesis is a highly orchestrated multi-step hier-
archical process tightly regulated by the temporal gene
expression regulation of transcription factors that
involves the proliferation, differentiation and maturation
of a very small population of self-renewing, CD34
+
HSPCs into various specialized and distinct blood cell
types. During this process, cellular speciﬁcation is initiated
by primary lineage determinants which ‘transcriptionally
prime’ hematopoietic progenitors to establish a low-level
expression of a mixed lineage pattern of gene expression.
The primary determinants will differentiate the
124 Nucleic Acids Research, 2012,Vol. 40,No. 1hematopoietic progenitors along a particular cell fate and
this commitment is subsequently regulated by secondary
transcription factors which function promoting a speciﬁc
cell fate by repressing commitment into alternate blood
lineages (35,36). In addition to transcription factors (37),
cytokines (38) and miRNA (39) have long been proposed
to participate in gene regulation during hematopoiesis.
Nonetheless, global mechanisms involved in this process
are still incompletely understood.
Promoter DNA demethylation is envisioned to be an
important mechanism controlling the activation of
speciﬁc genes within the hematopoietic system. Examples
include the genes coding for myeloperoxidase (7), globin
(8,9), c-fms (10), lysozyme (11), G-CSF receptor (12),
PRF1 (13), GPVI/GP6 (14) and FOXP3 (15). As
promoter DNA methylation is also implicated in the
genome-wide establishment of differentiation programs
in hESC (30,40), we hypothesized that promoter
demethylation may contribute to genome-wide hemato-
poietic gene activation during hematopoiesis. We thus
ﬁrst evaluated the potential role of promoter DNA
demethylation in a variety of somatic tissues by combining
genome-wide promoter methylation and gene expression
approaches in an attempt to identify promoter
demethylated genes in a variety of terminally
differentiated human primary tissues. Interestingly, this
approach revealed that promoter demethylation-
associated gene regulation is more frequent in the hemato-
poietic system than in non-hematopoietic tissues (463
genes demethylated in blood versus an average of 241
demethylated genes in non-hematopoietic samples.
Although less frequent, promoter demethylation in
Figure 3. Promoter methylation and expression of ten key genes of the hematopoietic system. For each gene, we depict (from top to bottom): the
diagram showing the genomic region surrounding the transcriptional start site (TSS, arrow). Thin black vertical bars indicate CpG position and a
grey horizontal bar indicates the location (distance in base pair from TSS) of the probe used in methylation arrays and validated by pyrosequencing
in the indicated samples; percentage of promoter methylation as detected in the pyrosequencing reaction; percentage of promoter methylation as
detected in the Illumina Inﬁnium array and mRNA expression relative to GAPDH as measured by qRT–PCR in the indicated samples (n=3,
mean±SD).
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Gene set GO Tissue-speciﬁc expression
GO Term P-value P-value
Neutrophils Biological process UNIPROT Tissue
Defense response 5.41E-06 Neutrophil 4.07E-04
Response to other organism 5.60E-06
Defense response to bacterium 5.63E-06
Response to biotic stimulus 1.15E-05
Response to stimulus 6.40E-05
Oxygen and reactive oxygen species metabolic process 9.46E-05
Multi-organism process 9.74E-05
Immune system process 1.58E-04
Response to bacterium 3.23E-04
Response to stress 1.36E-03
Cell component
Extracellular region 1.55E-04
Extracellular space 9.50E-03
Intrinsic to membrane 2.21E-02
NK cells Biological process
Defense response 3.89E-03 None
Cell surface receptor linked signal transduction 2.08E-02
Behavior 2.27E-02
Regulation of cytokine production 2.38E-02
G-protein coupled receptor protein signaling pathway 2.96E-02
Response to external stimulus 3.68E-02
Response to stimulus 3.84E-02
Immune system process 4.33E-02
Cell component
Extracellular region 1.37E-02
B cells Biological process UNIPROT tissue
Immune response 1.60E-10 Spleen 2.75E-05
Immune system process 2.07E-09 b-cell 1.34E-03
Defense response 1.28E-04 Lymph 1.28E-02
Response to stimulus 7.24E-04 Lymph node 2.99E-02
Regulation of immune system process 1.09E-02
Inﬂammatory response 1.12E-02
Regulation of lymphocyte activation 1.30E-02
Response to other organism 1.59E-02
Taxis 1.83E-02
Chemotaxis 1.83E-02
Cell component
Extracellular region 3.43E-06
Integral to plasma membrane 2.55E-03
Intrinsic to plasma membrane 3.13E-03
Plasma membrane part 5.85E-03
Plasma membrane 9.88E-03
CD4 T cells Biological process
Response to stimulus 1.66E-02 None
Potassium ion transport 2.71E-02
Defense response 2.85E-02
Monovalent inorganic cation transport 3.33E-02
Immune response 3.99E-02
Cell component
Extracellular region 3.64E-04
Extracellular region part 1.20E-03
Extracellular space 1.62E-03
CD8 T cells Biological process
Monovalent inorganic cation transport 5.91E-03 None
Potassium ion transport 6.90E-03
Homeostatic process 7.34E-03
Regulation of catabolic process 2.18E-02
Genetic imprinting 2.40E-02
Ion transport 2.48E-02
Cell component
Plasma membrane 3.76E-02
(continued)
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Gene set GO Tissue-speciﬁc expression
GO Term P-value P-value
All hematologic lineages Biological process UNIPROT tissue
Immune system process 4.59E-04 Blood 1.69E-05
Immune response 1.27E-03 Lymph 1.10E-04
Leukocyte activation 3.31E-03 Spleen 1.75E-03
Signal transduction 6.17E-03
Cell activation 7.16E-03
T cell activation 1.55E-02
Myeloid leukocyte activation 1.68E-02
Regulation of cellular localization 2.49E-02
Cell component
Plasma membrane 1.59E-03
Integral to plasma membrane 3.40E-03
Intrinsic to plasma membrane 3.94E-03
Plasma membrane part 1.19E-02
A
B
Figure 4. Promoter methylation and expression levels of hematopoietic genes in CD34
+ HSPCs, cells differentiated from CD34
+ and iPSCs
generated from CD34
+ HSPCs. (A) High purity sorted CB-derived CD34
+ HSPCs (top middle panel) were differentiated in vitro (Diff-CD34) for
14 days in the presence of SCF, GM-CSF, IL3 and EPO. Granulocyte (CFU-G), monocyte (CFU-M), granulo-monocyte (CFU-GM) and erythroid
(BFU-E) colony forming units were scored by light microscopy (right panels). Additionally, CB-derived CD34
+ HSPCs were induced to travel back
in development by generating iPSCs through ectopic expression of Oct4, Klf4, Sox2 and c-Myc (left panel shows a phase contrast image of a
CD34-iPSC). The bottom panel shows a scatter plot of remethylated genes in CD34-iPSC (red) (Supplementary Table S13) and demethylated genes
in the differentiated CD34 progeny (Diff–CD34) (green) (Supplementary Table S12). (B) Promoter methylation and expression of HLA-DR, CD31
and PIK3CD. Methylation and expression for each gene is indicated as in Figure 3. Expression by ﬂow cytometry of each gene in CD34-iPSC (top
panel) and CD34
+ HSPCs (bottom panel). For PIK3CD, WB analysis was performed in CD34
+ HSPCs, CD34-iPSC and Diff-CD34 (b-actin was
used as loading control).
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tissue differentiation, as some demethylated genes
identiﬁed in non-hematopoietic tissues are also important
in the identity or function of the speciﬁc tissue in which
they are demethylated, in agreement with previous data
(41). Examples include MYT1 (42) and RTP1 (43) in
brain, OBSCN (44) and MYOT (45) in muscle,
DAAO (46) and KYNU (47) in liver and TG (48) in
thyroid tissue.
Upon comparing the genome-wide promoter methyla-
tion and gene expression status of a variety of hESC lines,
somatic CD34
+HSPCs and ﬁve abundant white blood cell
types, we identiﬁed 694 genes (Supplementary Table S11),
highly enriched for hematopoietic-related functions, that
undergo promoter DNA demethylation speciﬁcally during
hematopoiesis. These genes were completely hypermeth-
ylated in hESCs and progressively lost promoter methyla-
tion throughout hematopoietic developmental stages in a
hematopoietic cell type-speciﬁc fashion. Out of the 694
genes, 523 (75.36%) were not demethylated in CD34
+
HSPCs. CD34
+ HSPCs are non-cultured primary cells,
suggesting that the in vitro culture is unlikely to be respon-
sible for the hypermethylation of the genes found
demethylated in a hematopoietic lineage-dependent
fashion (30). Importantly, most of the genes not
demethylated in CD34
+ HSPCs (98.5%) become
demethylated in hematopoietic terminally differentiated
cell types whilst most of the genes that are demethylated
in CD34
+ cells (90.73%) remained demethylated in all
hematopoietic terminally differentiated cell types
analyzed. Although CD34
+ HSPCs are commonly con-
sidered hematopoietic precursors, some studies have
shown that they are composed by a heterogeneous popu-
lation of cells (49) with only a minor fraction potentially
differentiating into lymphocytes. We have to consider the
possibility that some of the methylation differences
observed in lymphoid lineages, such as CD4
+ or CD8
+,
compared to CD34
+ cells, which have been described as
demethylation events might be in fact already present in
lymphoid progenitor cells in the pool of CD34
+cells, and
go undetected by the methylation array due to their
scarcity. Further analyses of puriﬁed subpopulations of
hematopoietic progenitors are thus needed to clarify this
issue. Collectively, our data suggest that promoter
demethylation is associated with the regulation of
hematopoietic-speciﬁc genes in two developmental
waves: pan-hematopoietic genes and hematopoietic
lineage-speciﬁc genes.
Recent work suggest that promoter DNA
demethylation is important in mouse (32,50) and human
hematopoiesis (51). Ji et al. (32) analyzed hematopoietic
progenitors with CHARM and, with the same cut-offs
used in our study, their data show 68 genes that become
demethylated in myeloid or lymphoid progenitors
(Supplementary Table S14 and Supplementary Figure
S3). Borgel et al. (50) used MeDip-chip to analyze differ-
ent embryonic stages and they identiﬁed eight hematopoi-
etic genes that were hypermethylated during the
embryonic development and that became demethylated
in hematological cells. The genes identiﬁed in the three
studies (Ji’s, Borgel’s and ours) were quite different
(Supplementary Table S14 and Supplementary Figure
S3). Indeed, no genes were common to the three studies,
and only eight were common to any two of the studies. In
our work, we identiﬁed 686 genes that had not been
identiﬁed by Ji or Borgel (Supplementary Table S14 and
Supplementary Figure S3). It is possible that these genes
are not regulated by promoter demethylation in mice or
that our methylation arrays were more efﬁcient in iden-
tifying these particular sequences. The fact that none of
the genes identiﬁed by Borgel were identiﬁed by Ji suggests
that the technology used is an important factor in
determining the ﬁnal set of identiﬁed genes.
Bocker et al. (51) employed the same methylation arrays
used in our study and identiﬁed 770 demethylated CpG
sites (change  15%) in myeloid cells (51). We identiﬁed 93
CpG sites in neutrophils and most (86%) of them are
common to Bocker’s study (Supplementary Figure S4).
The discrepancy might be due to the inclusion of other
types of terminally differentiated hematologic cells,
non-hematologic tissues and embryonic stem cells in our
study. Indeed, the inclusion of non-hematologic tissues
can be an advantage of our study over the other studies
as allowed for the identiﬁcation of genes that become
demethylated exclusively in hematologic tissues. For
instance, our results indicate that 98 of the CpG sites
identiﬁed by Bocker et al., can be also methylated at low
levels in other non-hematologic tissues (Supplementary
Figure S4).
Bocker et al. showed that promoter methylation of
CD34
+ cells can change over time. Since we used CD34
+
cells obtained from umbilical CB, it is possible that some
of our CpG sites may not have been truly hematologic
genes due to the aging-dependent DNA methylation
change reported by Bocker et al. To address this issue,
we used our selection criteria and the data provided by
Bocker et al. to identify genes demethylated in old versus
young CD34
+ cells ( 70% methylation in young CD34
+
cells and <30% methylation in old CD34
+ cells). We
identiﬁed three CpG sites that became demethylated in
old CD34
+ (Supplementary Table S15) cells and only
one of them coincided with the CpG sites identiﬁed in
our study (Supplementary Table S15). Moreover, most
(95.9%) of the CpG sites identiﬁed in our study
remained as hematological-speciﬁc demethylated CpG
sites when we used the data from adult CD34
+ cells
from Bocker et al. (Supplementary Figure S5). These
results indicate that, in general, the CpG sites identiﬁed
in our study become speciﬁcally demethylated during
hematopoietic linage determination rather than during
ontogenic development. Collectively, the results of the
four studies suggest that promoter demethylation is an
important factor in hematopoiesis but that further
research is needed to fully characterize the role of
promoter demethylation in mouse and human
hematopoiesis.
The comparison of our methylation data with
genome-wide gene expression data showed that the role
of promoter demethylation during hematopoiesis is more
complex. We found that regardless of the methylation
status in CD34
+ HSPCs, promoter demethylation did
not necessarily involve gene activation/overexpression.
128 Nucleic Acids Research, 2012,Vol. 40,No. 1This concurs with a previous study (52) and with a recent
report showing that active demethylation in human
post-mitotic hematological cells does not correlate with
transcription levels (53). A possible explanation for the
lack of expression of some demethylated genes is that
promoter demethylation has at least, two distinct target
gene-dependent effects: (i) direct mediation of gene
overexpression or (ii) priming of the gene for eventual
activation. This possibility is supported by the fact that
many of the demethylated genes identiﬁed in this study are
expressed at speciﬁc stages of the hematopoietic differen-
tiation (i.e. hematopoietic progenitor cells or terminally
differentiated cells). Among the genes we chose to
analyze, examples of the ﬁrst scenario include CD19, a
B cell-speciﬁc receptor that is demethylated and expressed
exclusively in B cells (54), and PRF1, a cytolytic protein
demethylated and expressed in cytotoxic CD8
+T cells and
NK cells (55). On the other hand, genes whose promoter
demethylation does not necessarily result in gene activa-
tion include CD28 (56) and HLA-DR (57). Some of these
genes whose demethylation does not imply immediate ac-
tivation are expressed later on in response to cell transition
to an active state during an immune response. These
include g-IFN (demethylated in CD8
+ T cells) and
FAS-L (demethylated in CD4
+ T cells, CD8
+ T cells and
NK cells) (Supplementary Table S8), which are expressed
upon T cell activation speciﬁcally at the site of an immune
response and in lymphoid organs (58). This observation,
together with our data, hint that promoter demethylation
might be important in priming speciﬁc hematopoietic
genes for activation/expression in response to external
stimuli.
To study the role of promoter demethylation in hem-
atopoiesis in more detail, we analyzed the genome-wide
demethylation proﬁles of in vitro-differentiated CD34
+
progenitors and determined the remethylation rate of
CD34
+ HSPCs demethylated genes in CD34
+-derived
iPS cells. In vitro differentiation of CD34
+ progenitors
resulted in demethylation of 29.7% of genes previously
found to be demethylated in all blood cell lineages
analyzed. CD34
+-derived iPS cells restored the embryonic
methylation patterns to most, but not all demethylated
genes (80.1%), in line with recent works reporting incom-
plete epigenetic reprogramming in these cells (59) yet
showing that promoter methylation-associated repression
of hematopoietic genes is closely associated with stemness.
Although our data suggest that promoter
demethylation might play a role in mediating genome-
wide gene activation during hematopoiesis, some hemato-
poietic genes do not appear to use this epigenetic mechan-
ism. One example is the cytotoxic T cell-speciﬁc antigen
CD8, which is demethylated in hESC and in all hemato-
poietic lineages, but is expressed speciﬁcally in CD8
+ T
cells (60). We cannot completely rule out a role for
promoter demethylation in controlling hematopoietic ex-
pression of such genes, as methylation changes might
occur in a promoter region different from that included
in the methylation arrays. Alternatively, it should be kept
in mind that the generation of mature and functional T
cells and B cells relies upon successful development and
selection processes through secondary lymphoid organs
such as thymus and spleen. Therefore, the expression of
many hematopoietic genes and receptors being expressed
during maturation in speciﬁc hematopoietic organs may
be controlled by yet unknown temporal and site-speciﬁc
epigenetic mechanisms. Some genes found to be
demethylated during hematopoiesis were previously
shown to be aberrantly hypermethylated in hematological
malignancies. These include RUNX3 (61), CD79B, CD19
and TCL1 (62,63). As these genes are hypermethylated in
hESCs and CD34
+HSPCs, the aberrant process in cancer
could be understood as a defect in establishing an
unmethylated promoter landscape during differentiation
rather than as an anomalous process of de novo
hypermethylation. In summary, we show that promoter
demethylation might be involved in the activation of hem-
atopoietic genes during hematopoiesis. Our data represent
a genome-wide promoter demethylation landscape of
human hematopoietic differentiation (Figure 5).
Hematopoiesis is nonetheless a highly orchestrated
multi-step hierarchical process much more complex than
described here. It involves many hematopoietic organs
(bone marrow, PB, spleen, thymus, liver, etc.), many inter-
mediate stages of differentiation (64) and other
less-abundant blood lineages not studied here (monocytes,
basophils, eosinophils, dendritic cells, etc.). Further
studies are thus needed to completely decipher the role
of DNA methylation during hematopoiesis.
Figure 5. Cartoon depicting the overall methylation levels of hemato-
poietic genes at different developmental/differentiation stages: hESC,
CD34
+ HSPCs and mature hematopoietic cell types (undifferentiated
stages, purple nuclei; neutrophils, pink nucleus; lymphoid cells, blue
nuclei). For each differentiation stage, the heatmap shows the methy-
lation levels of a selected group of hypermethylated genes in hESCs
that are demethylated in that cell type (Supplementary Table S11).
Names of some key blood genes are mapped at the right of each methy-
lation heatmap.
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